NEW YORK — Fujifilm said on Monday that it has agreed to acquire Inspirata's global digital pathology business, which includes its Dynamyx digital pathology software, for an undisclosed amount.
Inspirata said that the divestiture of its digital pathology operations would enable it to focus on its cloud-based, enterprise-focused software as a service for oncology informatics.
Dynamyx, which is CE-IVD marked and received US Food and Drug Administration clearance earlier this year, enables the use of whole-slide images from different scanning vendors instead of traditional glass slides for primary diagnosis. It is installed in medical facilities that handle large volumes of pathology images across multiple lab locations, allowing the use of a mix of laboratory and diagnostic technologies, according to Fujifilm.
Fujifilm acquired certain distribution rights to the software in mid-2020.
Under the terms of the deal, which is expected to close in early 2023, Inspirata's digital pathology operations, employees, and customers will become part of Tokyo-based Fujifilm's medical informatics business. Financial and other terms were not disclosed.
"Acquiring Inspirata's digital pathology business allows Fujifilm to be an even stronger healthcare partner, bridging a technological gap between pathology, radiology, and oncology to facilitate a more collaborative approach to care delivery across the enterprise," Fujifilm President and CEO Teiichi Goto said in a statement.
The transaction allows Tampa, Florida-based Inspirata "to align our resources with the broadening of our long-term strategic vision to expand the reach of our Trial Navigator and E-Path solutions [for clinical trial patient matching and cancer reporting, respectively] among our existing and prospect customers at leading academic medical centers, [National Cancer Institute]-designated cancer centers, and large healthcare networks," Inspirata Chairman and CEO Satish Sanan said in a statement.